Cipher Pharmaceuticals Inc
TSX:CPH

Watchlist Manager
Cipher Pharmaceuticals Inc Logo
Cipher Pharmaceuticals Inc
TSX:CPH
Watchlist
Price: 12.9 CAD 1.1% Market Closed
Market Cap: 330.4m CAD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CPH stock under the Base Case scenario is 7.29 CAD. Compared to the current market price of 12.9 CAD, Cipher Pharmaceuticals Inc is Overvalued by 43%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CPH Relative Value
Base Case
7.29 CAD
Overvaluation 43%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.1
P/S
P/S
Price to Sales
6.1
vs History
22
vs Industry
20
Median 3Y
4.7
Median 5Y
3.1
Industry
2.5
Forward
4.7
More Details
26
P/E
P/E
Price to Earnings
26
vs History
1
vs Industry
25
Median 3Y
6.3
Median 5Y
5.8
Industry
21.1
Forward
14.9
More Details
11.3
P/OCF
P/OCF
Price to OCF
11.3
vs History
14
vs Industry
34
Median 3Y
6.6
Median 5Y
4.6
Industry
16.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
28
Median 3Y
4.9
Median 5Y
4.7
Industry
23.7
More Details
2.3
P/B
P/B
Price to Book Value
2.3
vs History
12
vs Industry
35
Median 3Y
1.4
Median 5Y
1.1
Industry
2.1
More Details
6.6
EV/S
EV/S
Enterprise Value to Sales
6.6
vs History
14
vs Industry
18
Median 3Y
2.9
Median 5Y
1.6
Industry
2.6
Forward
5.1
More Details
9.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
9.1
vs History
14
vs Industry
21
Median 3Y
3.6
Median 5Y
2
Industry
5.1
More Details
20.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
20.2
vs History
11
vs Industry
18
Median 3Y
5.4
Median 5Y
2.7
Industry
12.4
Forward
10.2
More Details
35.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
35.6
vs History
3
vs Industry
14
Median 3Y
6.1
Median 5Y
3
Industry
15.7
Forward
15.1
More Details
12.1
EV/OCF
EV/OCF
Enterprise Value to OCF
12.1
vs History
12
vs Industry
33
Median 3Y
4
Median 5Y
2.5
Industry
14.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
31
Median 3Y
2.5
Median 5Y
2.3
Industry
17.1
More Details
1.9
EV/IC
EV/IC
Enterprise Value to IC
1.9
vs History
19
vs Industry
38
Median 3Y
1.6
Median 5Y
1
Industry
1.8
More Details

Multiples Across Competitors

CPH Competitors Multiples
Cipher Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Cipher Pharmaceuticals Inc
TSX:CPH
330.5m CAD 6.1 26 20.2 35.6
US
Eli Lilly and Co
NYSE:LLY
730.4B USD 14.9 65.8 35.3 38.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
364B USD 4.1 16.7 12.2 16
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.6 19.1 13.2 15.2
CH
Roche Holding AG
SIX:ROG
207.2B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
186.3B CHF 4.3 17.8 10.5 14.1
UK
AstraZeneca PLC
LSE:AZN
161.6B GBP 4 28.2 130.8 197.2
US
Merck & Co Inc
NYSE:MRK
201.7B USD 3.2 11.6 8.6 10.4
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
136.6B USD 2.2 17.3 7.5 10.5
P/E Multiple
Earnings Growth PEG
CA
Cipher Pharmaceuticals Inc
TSX:CPH
Average P/E: 25.3
26
16%
1.6
US
Eli Lilly and Co
NYSE:LLY
65.8
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.7
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.1
18%
1.1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
17.8
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.6
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.3
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Cipher Pharmaceuticals Inc
TSX:CPH
Average EV/EBITDA: 395.9
20.2
35%
0.6
US
Eli Lilly and Co
NYSE:LLY
35.3
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.2
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10.5
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.6
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Cipher Pharmaceuticals Inc
TSX:CPH
Average EV/EBIT: 1 700.6
35.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.6
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
15.2
14%
1.1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
14.1
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.2
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.4
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
10%
1

See Also

Summary
CPH intrinsic value, competitors valuation, and company profile.
DCF Valuation
CPH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CPH stock valuation using valuation multiples.
Wall Street Estimates
CPH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CPH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 263,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.